| Name | Napabucasin |
| Description | Napabucasin (BBI608) is an orally available Stat3 and Y cell stemness inhibitor. |
| Cell Research | For cancer stem cells, spheres are dissociated and plated under cancer stem cell culture conditions on coated 96-well plates. After 72 h of culture, wells are dosed with the indicated compounds. Seventy-two hours or 24 h after dosing, CellTiter-Glo 2.0 is added to each well, and the luminescence is measured as described by the manufacturer. IC50 values are calculated by fitting a four parameter dose–response curve to normalized data using GraphPad Prism software. For bulk cells, cells are plated at 5,000 cells per well on 96-well plates. Twenty-four hours after plating, cells are treated with the indicated compounds. Viability is determined at 72 h as described above.(Only for Reference) |
| In vitro | Napabucasin downregulates stemness gene expression driven by Stat3 and cancer stemness properties, and effectively inhibits self-renewal of stemness-high cancer cells with IC50 ranged from 0.291~1.19 μM, on inhibition on normal stem cells. [1] |
| In vivo | In mice bearing PaCa-2 xenografts, Napabucasin (20 mg/kg, i.p.) significantly inhibits tumor growth, relapse and metastasis. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 6.88 mg/mL (28.64 mM), Sonication is recommended.
acetonitrile : 0.8 mg/mL (3.33 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | STAT3 | STAT | Napabucasin | Inhibitor | inhibit | BBI-608 | BBI 608 |
| Inhibitors Related | Flubendazole | HODHBt | Nifuroxazide | Balsalazide disodium dihydrate | Astaxanthin | Cryptotanshinone | Niclosamide | Diosgenin | 2,4,5-Trimethoxybenzoic acid | Niclosamide olamine | Artesunate | Raspberry ketone glucoside |
| Related Compound Libraries | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
